Hemab Therapeutics (NASDAQ:COAG) Shares Down 4.8% – Should You Sell?

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) shares dropped 4.8% during mid-day trading on Monday . The company traded as low as $44.86 and last traded at $45.26. 355,374 shares were traded during trading, an increase of 13% from the average daily volume of 315,698 shares. The stock had previously closed at $47.55.

Analyst Ratings Changes

COAG has been the subject of several analyst reports. Wall Street Zen upgraded shares of Hemab Therapeutics to a “hold” rating in a report on Saturday, May 9th. The Goldman Sachs Group assumed coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They set a “buy” rating and a $36.00 price target on the stock. Zacks Research raised shares of Hemab Therapeutics to a “hold” rating in a research report on Wednesday, May 27th. Wedbush reiterated an “outperform” rating and issued a $55.00 price objective (up from $42.00) on shares of Hemab Therapeutics in a research note on Monday, July 13th. Finally, Jefferies Financial Group lifted their target price on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, Hemab Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $48.00.

Hemab Therapeutics Stock Up 3.2%

The company has a 50 day simple moving average of $35.19. The firm has a market cap of $2.17 billion and a P/E ratio of -1.94.

Hemab Therapeutics (NASDAQ:COAG) last posted its quarterly earnings data on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Insiders Place Their Bets

In other news, major shareholder Ra Capital Management, L.P. purchased 61,523 shares of the company’s stock in a transaction dated Tuesday, June 16th. The shares were purchased at an average price of $24.98 per share, with a total value of $1,536,844.54. Following the transaction, the insider directly owned 6,444,637 shares of the company’s stock, valued at approximately $160,987,032.26. This represents a 0.96% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders acquired 130,112 shares of company stock worth $3,237,127 over the last three months.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.